ARS Pharmaceuticals (SPRY) EBIT Margin (2022 - 2026)
ARS Pharmaceuticals (SPRY) posted EBIT Margin of 265.18% for Q1 2026, down 79.62% sequentially from 147.63% in Q4 2025, and up 20111.0% YoY from N/an in Q1 2025.
ARS Pharmaceuticals (SPRY) EBIT Margin (2022 - 2026) Analysis & Trends
ARS Pharmaceuticals has reported EBIT Margin for 5 years, with the latest figure at 265.18% in Q1 2026.
- Quarterly EBIT Margin rose 20111.0% year-over-year to 265.18% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 204.49% (down 17662.0% YoY) and the FY2025 annual result came in at 212.92%, down 20947.0% from the prior year.
- EBIT Margin retreated to 265.18% in Q1 2026 per SPRY's latest filing, from 147.63% in the prior quarter.
- Over five years, EBIT Margin peaked at 54.51% in Q4 2024 and troughed at 206030.0% in Q2 2023.
- A 5-year average of 23919.37% and a median of 1051.64% in 2024 frame the typical range for EBIT Margin.
- The sharpest annual moves came in 2023 and 2024: EBIT Margin plunged 20466276 bps in 2023, then surged 20296200 bps in 2024.
- Over 5 years, EBIT Margin stood at 3507.94% in 2022, then slumped by 5773 bps to 206030.0% in 2023, then soared by 100 bps to 54.51% in 2024, then slumped by 371 bps to 147.63% in 2025, then slumped by 80 bps to 265.18% in 2026.
- According to Business Quant data, EBIT Margin over the past three periods registered 265.18%, 147.63%, and 163.66% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -105.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | ARS Pharmaceuticals | 561.88 Mn | 418.03 Mn | - | -182.62% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -182.62% |
| Mar 31, 2026 | -265.18% |
| Dec 31, 2025 | -147.63% |
| Sep 30, 2025 | -163.66% |
| Jun 30, 2025 | -302.95% |
| Mar 31, 2025 | -466.29% |
| Dec 31, 2024 | 54.51% |
| Sep 30, 2024 | -1,051.64% |
| Jun 30, 2024 | -3,068.00% |
| Jun 30, 2023 | -206,030.00% |
| Mar 31, 2023 | -93,565.00% |
| Sep 30, 2022 | -3,507.94% |
| Jun 30, 2022 | -1,367.24% |
| Mar 31, 2022 | -1,070.74% |